Stefania Pfeiffer-Marek

Dr. Stefania Pfeiffer-Marek

Sanofi, Global CMC Development, Frankfurt am Main, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AEAndreas Evers
Andreas Evers
DCDidier Clenet
Didier Clenet
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
A crucial aspect of pharmaceutical development is the demonstration of long-term stability of the drug product. Biopharmaceuticals, such as proteins or peptides in liquid formulation, are typically administered via parental routes and should be stable over the shelf life, which generally includes a storing period (e.g., two years at 5 °C) and optionally an in-use period (e.g., 28 days at 30 °C). Herein, we present a case study where chemical degradation of SAR441255, a therapeutic peptide, in different formulations in combination with primary packaging materials was analyzed under accelerated conditions to derive long-term stability predictions for the recommended storing conditions (two years at 5 °C plus 28 days at 30 °C) using advanced kinetic modeling. These predictions served as a crucial decision parameter for the entry into clinical development. Comparison with analytical data measured under long-term conditions during the subsequent development phase demonstrated a high prediction accuracy. These predictions provided stability insights within weeks that would otherwise take years using measurements under long-term stability conditions only. To our knowledge, such in silico studies on stability predictions of a therapeutic peptide using accelerated chemical degradation data and advanced kinetic modeling with comparisons to subsequently measured real-life long-term stability data have not been described in literature before.

27 January 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Katharina DauerKatharina Dauer
Katharina Dauer
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
WKWalter Kamm
Walter Kamm
Karl G. WagnerKarl G. Wagner
Karl G. Wagner
High-throughput light scattering instruments are widely used in screening of biopharmaceutical formulations and can be easily incorporated into processes by utilizing multi-well plate formats. High-throughput plate readers are helpful tools to assess the aggregation tendency and colloidal stability of biological drug candidates based on the diffusion self-interaction parameter (kD). However, plate readers evoke issues about the precision and variability of determined data. In this article, we report about the statistical evaluation of intra- and inter-plate variability (384-well plates) for the kD analysis of protein and peptide solutions. ANOVA revealed no significant differences between the runs. In conclusion, the reliability and precision of kD was dependent on the plate position of the sample replicates and kD value. Positive kD values (57.0 mL/g, coefficients of variation (CV) 8.9%) showed a lower variability compared to negative kD values (−14.8 mL/g, CV 13.4%). The variability of kD was not reduced using more data points (120 vs. 30). A kD analysis exclusively based on center wells showed a lower CV (<2%) compared to edge wells (5–12%) or a combination of edge and center wells (2–5%). We present plate designs for kD analysis within the early formulation development, screening up to 20 formulations consuming less than 50 mg of active pharmaceutical ingredient (API).

1 April 2019 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
AEAndreas Evers
Andreas Evers
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
MBMartin Bossart
Martin Bossart
CHChristoph Heubel
Christoph Heubel
USUrsula Stock
Ursula Stock
MWMichael Wagner
Michael Wagner

31 March 2021 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Katharina DauerKatharina Dauer
Katharina Dauer
WKWalter Kamm
Walter Kamm
KWKarl Gerhard Wagner
Karl Gerhard Wagner
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek

3 September 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MWMartin Wolff
Martin Wolff
KGKlaus Gast
Klaus Gast
AEAndreas Evers
Andreas Evers
MKMichael Kurz
Michael Kurz
SPStefania Pfeiffer-Marek
Stefania Pfeiffer-Marek
Anja ThalhammerAnja Thalhammer
Anja Thalhammer
Exendin-4 is a pharmaceutical peptide used in the control of insulin secretion. Structural information on exendin-4 and related peptides especially on the level of quaternary structure is scarce. We present the first published association equilibria of exendin-4 directly measured by static and dynamic light scattering. We show that exendin-4 oligomerization is pH dependent and that these oligomers are of low compactness. We relate our experimental results to a structural hypothesis to describe molecular details of exendin-4 oligomers. Discussion of the validity of this hypothesis is based on NMR, circular dichroism and fluorescence spectroscopy, and light scattering data on exendin-4 and a set of exendin-4 derived peptides. The essential forces driving oligomerization of exendin-4 are helix–helix interactions and interactions of a conserved hydrophobic moiety. Our structural hypothesis suggests that key interactions of exendin-4 monomers in the experimentally supported trimer take place between a defined helical segment and a hydrophobic triangle constituted by the Phe22 residues of the three monomeric subunits. Our data rationalize that Val19 might function as an anchor in the N-terminus of the interacting helix-region and that Trp25 is partially shielded in the oligomer by C-terminal amino acids of the same monomer. Our structural hypothesis suggests that the Trp25 residues do not interact with each other, but with C-terminal Pro residues of their own monomers.